Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 08, 2021 08:30 ET | Source: Checkpoint Therapeutics, Inc

Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer

WALTHAM, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the...
November 04, 2021 16:30 ET | Source: Checkpoint Therapeutics, Inc

Checkpoint Therapeutics Reports Third Quarter 2021 Financial Results

WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial...
September 22, 2021 08:30 ET | Source: Checkpoint Therapeutics, Inc

Checkpoint Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

WALTHAM, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that...
September 09, 2021 08:30 ET | Source: Checkpoint Therapeutics, Inc

Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences

WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that...
August 05, 2021 16:30 ET | Source: Checkpoint Therapeutics, Inc

Checkpoint Therapeutics Reports Second Quarter 2021 Financial Results

NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial...
July 08, 2021 08:30 ET | Source: Checkpoint Therapeutics, Inc

Checkpoint Therapeutics to Participate in the Ladenburg Thalmann 2021 Healthcare Conference

NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James...
May 12, 2021 08:00 ET | Source: Checkpoint Therapeutics, Inc

Checkpoint Therapeutics Announces Completion of Enrollment in the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

Top-line results expected in 4Q 2021Targeting BLA submission in 1H 2022Market-disruptive pricing planned in $25 billion and growing PD-(L)1 market NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) --...
May 06, 2021 16:15 ET | Source: Checkpoint Therapeutics, Inc

Checkpoint Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Highlights

NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial...
March 09, 2021 16:30 ET | Source: Checkpoint Therapeutics, Inc

Checkpoint Therapeutics Reports Full-Year 2020 Financial Results and Recent Corporate Highlights

NEW YORK, March 09, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial...
March 04, 2021 08:00 ET | Source: Checkpoint Therapeutics, Inc

Checkpoint Therapeutics to Participate in H.C. Wainwright Global Life Sciences Virtual Conference

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James...